dextroamphetamine has been researched along with Autoimmune Demyelinating Disease, Peripheral in 1 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The daytime somnolence was confirmed objectively by polygraphic monitoring seven weeks to 4 1/2 months after the onset of clinical symptoms." | 1.27 | Mononucleosis and chronic daytime sleepiness. A long-term follow-up study. ( Guilleminault, C; Mondini, S, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guilleminault, C | 1 |
| Mondini, S | 1 |
1 other study available for dextroamphetamine and Autoimmune Demyelinating Disease, Peripheral
| Article | Year |
|---|---|
Mononucleosis and chronic daytime sleepiness. A long-term follow-up study.
Topics: Adolescent; Adult; Chronic Disease; Circadian Rhythm; Dextroamphetamine; Disorders of Excessive Somn | 1986 |